Daily Endocrinology Research Analysis
Analyzed 132 papers and selected 3 impactful papers.
Summary
Three standout endocrinology/metabolism papers advance mechanistic understanding and translational potential. A Cell Metabolism study identifies a brown fat–derived metabolite (3-hydroxystearic acid) that protects the liver from oxidative stress. Proteomics from the TODAY cohort reveals reproducible protein signatures predicting loss of glycemic control in youth-onset type 2 diabetes, while a Science Translational Medicine study shows a controlled-release mitochondrial protonophore attenuates atherogenesis in insulin-resistant mice.
Research Themes
- Brown adipose tissue endocrine signaling and liver protection
- Proteomic risk stratification in youth-onset type 2 diabetes
- Mitochondrial uncoupling as a cardiometabolic therapy
Selected Articles
1. Brown fat protects against hepatic oxidative stress by remodeling the circulating metabolome.
Using integrated metabolomics/lipidomics across BAT-ablated mice and human cohorts, the study shows BAT shapes the circulating metabolome, including enhanced clearance of branched-chain amino acids and triglycerides. It identifies 3-hydroxystearic acid as a BAT-derived, cold-inducible metabolite that reduces hepatic mitochondrial membrane potential and reactive oxygen species, limiting oxidative stress.
Impact: This work uncovers a new endocrine function of BAT via a defined metabolite (3-OHSA) that protects the liver, reframing BAT-liver crosstalk and offering a measurable biomarker of BAT activation.
Clinical Implications: 3-OHSA may serve as a biomarker of BAT activation and a lead for therapies that harness BAT to mitigate hepatic oxidative stress in metabolic disease. Strategies to enhance BAT activity or mimic 3-OHSA signaling could complement current MASLD and cardiometabolic risk management.
Key Findings
- BAT activity robustly remodels the circulating metabolome in mice and humans, including increased clearance of branched-chain amino acids and triglycerides.
- A cold-inducible, BAT-derived metabolite, 3-hydroxystearic acid (3-OHSA), was identified in circulation.
- 3-OHSA acted on the liver to lower mitochondrial membrane potential and reactive oxygen species, limiting hepatic oxidative stress.
Methodological Strengths
- Multi-system, integrated metabolomics/lipidomics across species (mouse-human) and compartments (serum, tissues, extracellular fluids, conditioned media).
- Convergent functional assays linking a specific metabolite (3-OHSA) to hepatic mitochondrial physiology.
Limitations
- Exact human sample sizes and clinical phenotyping details are not specified in the abstract.
- Translational efficacy and safety of targeting 3-OHSA signaling remain to be established in interventional human studies.
Future Directions: Prospective clinical studies validating circulating 3-OHSA as a BAT biomarker, mechanistic dissection of its receptor/targets, and interventional trials enhancing BAT or mimicking 3-OHSA to reduce hepatic oxidative injury.
Brown adipose tissue (BAT) regulates systemic metabolism beyond thermogenesis, yet the circulating mediators through which BAT communicates with other organs remain less explored. Here, we performed comprehensive serum metabolomics and lipidomics in BAT-ablated mice and human cohorts with varying BAT activity to delineate how BAT activity shapes the circulating metabolome. By integrating datasets across serum, tissues, extracellular fluids, and conditioned media, we assembled BAT-linked circulating molecular signat
2. Proteomic signatures of loss of glycemic control in youth-onset type 2 diabetes in the TODAY study.
In 374 youth with T2D followed for a mean of 10.8 years, 67 proteins were associated with loss of glycemic control after correction and adjustment. Plexin-B2 (HR 1.46) and semaphorin-6A (HR 1.31) were top signals and validated across independent youth and adult cohorts. Enrichment implicated axon guidance, immune, inflammatory, and metabolic pathways.
Impact: Establishes reproducible, cross-platform proteomic predictors of glycemic failure in youth-onset T2D, enabling biologically informed risk stratification beyond traditional markers.
Clinical Implications: Protein signatures (e.g., plexin-B2, semaphorin-6A) could inform early identification of youth at high risk for glycemic failure and guide timely therapy intensification and trial enrichment. Pathways highlighted may offer novel therapeutic targets.
Key Findings
- Quantified 7604 aptamers (6596 proteins); 67 proteins associated with loss of glycemic control after FDR correction and adjustment.
- Top predictors included plexin-B2 (HR 1.46) and semaphorin-6A (HR 1.31), validated in independent youth and adult cohorts.
- Pathway enrichment implicated axon guidance, immune response, inflammation, and metabolism in glycemic deterioration.
Methodological Strengths
- Long-term longitudinal design (mean 10.8 years) with external validation across multiple independent cohorts, including adults.
- High-dimensional proteomics (SomaScan 7K) with FDR control and multivariable adjustment.
Limitations
- Observational design precludes causal inference; residual confounding is possible.
- Platform-specific aptamer measurements may require cross-platform harmonization for clinical deployment.
Future Directions: Prospective validation with predefined thresholds, clinical utility studies for treatment decision support, and mechanistic work linking top proteins to β-cell decline and inflammation.
CONTEXT: Youth-onset type 2 diabetes (T2D) is characterized by accelerated β-cell decline and early treatment failure, and there is an urgent need to improve the understanding of molecular drivers of loss of glycemic control (LOGC). OBJECTIVE: To identify multiprotein signatures associated with loss of glycemic control (LOGC) in youth-onset T2D. DESIGN: Longitudinal observational study with a mean follow-up of 10.8 ± 3.8 years using data from the TODAY study, with external validation in three youth cohorts and one adult-onset T2D cohort. SETTING: Multicenter clinical research study. PARTICIPANTS: Participants from the TODAY study (N = 374; age 14 ± 2 years; 37% male), of whom 72% experienced LOGC over 10.8 ± 3.8 years. INTERVENTIONS: None. MAIN OUTCOME MEASURE: LOGC, defined as HbA1c ≥ 8% for ≥6 months or inability to discontinue insulin after acute metabolic decompensation. RESULTS: Plasma proteomics quantified 7604 aptamers representing 6596 proteins using the SomaScan 7 K platform. Sixty-seven proteins were associated with LOGC after false discovery rate correction and multivariable adjustment. Key proteins included plexin-B2 (HR: 1.46 [95% CI: 1.29-1.66]) and semaphorin-6A (HR: 1.31 [1.18-1.47]), which were also associated with glycemic outcomes in independent youth and adult cohorts. Enrichment analyses implicated pathways related to axon guidance, immune response, inflammation, and metabolism. CONCLUSIONS: Novel proteins involved in axon guidance, immune response, inflammation, and metabolism associated with LOGC in youth-onset T2D with proteins demonstrating consistent associations across the lifespan and proteomic platforms.
3. A controlled-release mitochondrial protonophore attenuates early- and late-stage atheroprogression in mice.
An oral controlled-release mitochondrial protonophore (CRMP) previously shown to reverse dyslipidemia and insulin resistance was tested in LDLR-deficient mice on a high-fat cholesterol diet. CRMP attenuated atherogenesis at both early and late stages, extending its benefits beyond steatosis and insulin sensitivity to vascular disease in a cardiometabolic model.
Impact: Demonstrates plaque-modifying efficacy of a systemically safe mitochondrial uncoupler in a stringent atherogenic model, strengthening the therapeutic rationale for targeting mitochondrial bioenergetics in cardiometabolic disease.
Clinical Implications: Supports advancing CRMP-like mitochondrial uncouplers to human studies for ASCVD prevention/treatment in insulin resistance, with careful dose–safety profiling and biomarker-driven patient selection.
Key Findings
- Oral CRMP, a controlled-release 2,4-dinitrophenol formulation, attenuated atherogenesis in LDLR-deficient mice on a high-fat cholesterol diet.
- Efficacy was observed across early and late stages of plaque progression, extending previous benefits beyond steatosis and insulin resistance.
- Builds on prior safety and metabolic efficacy data in rodents and nonhuman primates, supporting translational potential.
Methodological Strengths
- Use of a stringent cardiometabolic atherogenesis model (LDLR-deficient mice on HFCD).
- Therapeutic evaluation across both early and late disease stages, informing timing of intervention.
Limitations
- Preclinical murine study; human pharmacokinetics, safety margins, and efficacy remain to be established.
- Abstract does not provide dosing details, sample sizes, or mechanistic plaque biology endpoints.
Future Directions: IND-enabling toxicology and dose-finding, imaging-based atherosclerosis endpoints in large animals/humans, and biomarker strategies to monitor mitochondrial uncoupling in vivo.
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in patients with insulin resistance, and new therapies are urgently needed. We previously developed an orally administered formulation of 2,4-dinitrophenol, here termed controlled-release mitochondrial protonophore (CRMP), and showed that it safely reversed hypertriglyceridemia, hepatic steatosis, and insulin resistance in dysmetabolic rodents and nonhuman primates. Here, we investigated the therapeutic utility of CRMP for treating atherogenesis in a murine model of cardiometabolic syndrome [high-fat cholesterol diet (HFCD)-fed low-density lipoprotein receptor-deficient (